Prevention of beta-cell destruction in autoimmune diabetes: current approaches and future prospects.
Type 1 diabetes (T1D) is an autoimmune disease resulting from the destruction of pancreatic beta-cells. The main aim of treatment should be to prevent beta-cell destruction and preserve existing beta-cells in individuals with progressive autoimmunity. This can be achieved in several ways and in this chapter the authors have reviewed recent approaches that are currently being tested in animal models and human T1D patients under the following categories: i) antigen based therapy, ii) antibody-based therapy iii) other forms of therapy and iv) failed therapies.
Sedimbi
Saikiran K
SK
Department of Molecular Medicine and Surgery, Center for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Solna-17176, Stockholm, Sweden. saikiran.sedimbi@ki.se
Sanjeevi
Carani B
CB
D000818:Animals; D000906:Antibodies / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000737:chemistry; D000941:Antigens / Q000737:chemistry / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007108:Immune Tolerance; D007328:Insulin / Q000378:metabolism; D050417:Insulin-Secreting Cells / Q000166:cytology*; D051379:Mice; D016688:Mice, Inbred NOD; D008954:Models, Biological; D019444:Vaccines, DNA / Q000627:therapeutic use
D000906:Antibodies; D000911:Antibodies, Monoclonal; D000941:Antigens; D007328:Insulin; D019444:Vaccines, DNA